Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 AxoGenNatus MedicalTransMedics GroupSemler ScientificViewRay
SymbolNASDAQ:AXGNNASDAQ:NTUSNASDAQ:TMDXOTCMKTS:SMLRNASDAQ:VRAY
Price Information
Current Price$19.34$26.73$28.96$110.00$4.57
52 Week RangeBuyHoldBuyBuyBuy
MarketRank™
Overall Score1.51.11.61.21.3
Analysis Score2.30.03.31.51.3
Community Score2.91.92.32.52.8
Dividend Score0.00.00.00.00.0
Ownership Score1.71.71.70.01.7
Earnings & Valuation Score0.61.90.61.90.6
Analyst Ratings
Consensus RecommendationBuyHoldBuyBuyBuy
Consensus Price Target$23.75N/A$44.20$110.50$4.50
% Upside from Price Target22.80% upsideN/A52.62% upside0.45% upside-1.53% downside
Trade Information
Market Cap$785.68 million$904.78 million$776.76 million$738.87 million$717.17 million
Beta0.710.722.161.110.64
Average Volume240,577186,428808,61118,7521,990,863
Sales & Book Value
Annual Revenue$106.71 million$495.52 million$23.60 million$32.77 million$87.78 million
Price / Sales7.391.8333.9022.558.37
CashflowN/A$2.28 per shareN/A$3.15 per shareN/A
Price / CashN/A11.73N/A34.91N/A
Book Value$3.35 per share$12.21 per share$2.58 per share$2.00 per share$1.47 per share
Price / Book5.772.1911.2255.003.11
Profitability
Net Income$-29,140,000.00$-15,670,000.00$-33,550,000.00$15.08 million$-120,200,000.00
EPS($0.68)$1.24($2.36)$1.88($1.18)
Trailing P/E RatioN/AN/AN/A77.46N/A
Forward P/E RatioN/A23.65N/A48.46N/A
P/E GrowthN/AN/AN/A1.48N/A
Net Margins-22.98%-4.33%-131.35%32.08%-166.74%
Return on Equity (ROE)-19.83%3.87%-38.95%67.38%-63.41%
Return on Assets (ROA)-14.88%2.50%-24.10%52.42%-36.34%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.42%0.06%0.32%N/A0.26%
Current Ratio7.45%2.02%11.31%3.85%3.90%
Quick Ratio6.81%1.41%10.36%3.85%3.19%
Ownership Information
Institutional Ownership Percentage78.38%89.67%76.68%12.13%83.03%
Insider Ownership Percentage6.94%1.50%13.10%13.60%15.48%
Miscellaneous
Employees3461,48411086236
Shares Outstanding40.77 million33.87 million27.62 million6.72 million160.80 million
Next Earnings Date5/5/2021 (Confirmed)5/6/2021 (Confirmed)5/4/2021 (Confirmed)5/3/2021 (Estimated)5/6/2021 (Confirmed)
OptionableOptionableOptionableNot OptionableNot OptionableOptionable
SourceHeadline
Radiotherapy Market Opportunity, Challenges, Future Demands and Forecast by 2027: Covid-19 Impact and Recovery – Northern Gwinnett News - Northern Gwinnett News (NGwinnett.com)Radiotherapy Market Opportunity, Challenges, Future Demands and Forecast by 2027: Covid-19 Impact and Recovery – Northern Gwinnett News - Northern Gwinnett News (NGwinnett.com)
ngwinnett.com - April 22 at 1:41 PM
ViewRay, Inc. (NASDAQ:VRAY): The Stock for Success Over the Next Few MonthsViewRay, Inc. (NASDAQ:VRAY): The Stock for Success Over the Next Few Months
marketingsentinel.com - April 22 at 8:41 AM
Zacks: Analysts Anticipate ViewRay, Inc. (NASDAQ:VRAY) Will Post Quarterly Sales of $13.49 MillionZacks: Analysts Anticipate ViewRay, Inc. (NASDAQ:VRAY) Will Post Quarterly Sales of $13.49 Million
americanbankingnews.com - April 22 at 3:38 AM
Stock Traders Purchase Large Volume of Call Options on ViewRay (NASDAQ:VRAY)Stock Traders Purchase Large Volume of Call Options on ViewRay (NASDAQ:VRAY)
americanbankingnews.com - April 21 at 3:42 PM
ViewRay (NASDAQ:VRAY) Trading 7.4% Higher ViewRay (NASDAQ:VRAY) Trading 7.4% Higher
americanbankingnews.com - April 21 at 12:58 PM
 Brokerages Anticipate ViewRay, Inc. (NASDAQ:VRAY) to Announce -$0.17 Earnings Per Share Brokerages Anticipate ViewRay, Inc. (NASDAQ:VRAY) to Announce -$0.17 Earnings Per Share
americanbankingnews.com - April 20 at 6:14 AM
ViewRay Announces Conference Call for First Quarter 2021 Financial Results to be Held After Market on May 6, 2021 - PRNewswireViewRay Announces Conference Call for First Quarter 2021 Financial Results to be Held After Market on May 6, 2021 - PRNewswire
prnewswire.com - April 19 at 7:28 PM
ViewRay Announces Conference Call for First Quarter 2021 Financial Results to be Held After Market on May 6, 2021ViewRay Announces Conference Call for First Quarter 2021 Financial Results to be Held After Market on May 6, 2021
finance.yahoo.com - April 19 at 7:28 PM
ViewRay (NASDAQ:VRAY) Trading Down 3.9%ViewRay (NASDAQ:VRAY) Trading Down 3.9%
americanbankingnews.com - April 19 at 12:46 PM
ViewRay, Inc. (NASDAQ:VRAY) Given Consensus Rating of "Buy" by BrokeragesViewRay, Inc. (NASDAQ:VRAY) Given Consensus Rating of "Buy" by Brokerages
americanbankingnews.com - April 12 at 8:50 AM
Radiotherapy Market 2021 Highlights Recent Trends, Market Growth and Business Opportunities till 2027 – ROUGH Magazine - ROUGH MagazineRadiotherapy Market 2021 Highlights Recent Trends, Market Growth and Business Opportunities till 2027 – ROUGH Magazine - ROUGH Magazine
rough.asia - April 9 at 6:25 PM
AtriCure Names B. Kristine Johnson Board Chair - StreetInsider.comAtriCure Names B. Kristine Johnson Board Chair - StreetInsider.com
streetinsider.com - April 8 at 9:26 AM
Zacks: Brokerages Anticipate ViewRay, Inc. (NASDAQ:VRAY) Will Announce Quarterly Sales of $13.49 MillionZacks: Brokerages Anticipate ViewRay, Inc. (NASDAQ:VRAY) Will Announce Quarterly Sales of $13.49 Million
americanbankingnews.com - April 4 at 1:40 AM
Zacks: Brokerages Expect ViewRay, Inc. (NASDAQ:VRAY) Will Post Earnings of -$0.17 Per ShareZacks: Brokerages Expect ViewRay, Inc. (NASDAQ:VRAY) Will Post Earnings of -$0.17 Per Share
americanbankingnews.com - April 2 at 8:14 PM
ViewRay (NASDAQ:VRAY) Stock Rating Upgraded by BTIG ResearchViewRay (NASDAQ:VRAY) Stock Rating Upgraded by BTIG Research
americanbankingnews.com - April 1 at 10:12 AM
Should You Buy Viewray Inc (VRAY) Stock Friday Morning? - InvestorsObserverShould You Buy Viewray Inc (VRAY) Stock Friday Morning? - InvestorsObserver
investorsobserver.com - March 27 at 1:06 AM
ViewRay initiated buy at BTIG on management remarks - Seeking AlphaViewRay initiated buy at BTIG on management remarks - Seeking Alpha
seekingalpha.com - March 27 at 1:06 AM
New partnership enables access to state-of-the-art radiotherapy machine in Oxford - Mirage NewsNew partnership enables access to state-of-the-art radiotherapy machine in Oxford - Mirage News
miragenews.com - March 25 at 1:39 PM
ViewRay Inc.s chief operating officer is leaving the company - Crains Cleveland BusinessViewRay Inc.'s chief operating officer is leaving the company - Crain's Cleveland Business
crainscleveland.com - March 17 at 7:54 AM
If You Had Bought ViewRay (NASDAQ:VRAY) Stock A Year Ago, You Could Pocket A 224% Gain Today - Yahoo FinanceIf You Had Bought ViewRay (NASDAQ:VRAY) Stock A Year Ago, You Could Pocket A 224% Gain Today - Yahoo Finance
finance.yahoo.com - March 16 at 3:11 PM
If You Had Bought ViewRay (NASDAQ:VRAY) Stock A Year Ago, You Could Pocket A 224% Gain TodayIf You Had Bought ViewRay (NASDAQ:VRAY) Stock A Year Ago, You Could Pocket A 224% Gain Today
finance.yahoo.com - March 16 at 3:11 PM
ViewRay Announces Departure of Chief Operating Officer - BioSpaceViewRay Announces Departure of Chief Operating Officer - BioSpace
biospace.com - March 15 at 11:35 PM
ViewRay (VRAY) Announces Departure of Chief Operating Officer - StreetInsider.comViewRay (VRAY) Announces Departure of Chief Operating Officer - StreetInsider.com
streetinsider.com - March 15 at 6:35 PM
ViewRay COO Shahriar Martin named CEO at Cordis - Cleveland - The Business JournalsViewRay COO Shahriar Martin named CEO at Cordis - Cleveland - The Business Journals
bizjournals.com - March 15 at 6:35 PM
ViewRay - Seeking AlphaViewRay - Seeking Alpha
seekingalpha.com - March 15 at 6:35 PM
DateCompanyBrokerageAction
3/1/2021AxoGenSVB LeerinkBoost Price Target
3/1/2021AxoGenCanaccord GenuityBoost Price Target
1/12/2021AxoGenCantor FitzgeraldBoost Price Target
10/22/2020AxoGenGuggenheimInitiated Coverage
8/5/2020AxoGenBTIG ResearchReiterated Rating
8/7/2019AxoGenJMP SecuritiesLower Price Target
8/7/2019AxoGenWilliam BlairDowngrade
9/2/2020Natus MedicalRaymond JamesReiterated Rating
3/29/2021TransMedics GroupCowenBoost Price Target
3/9/2021TransMedics GroupMorgan StanleyBoost Price Target
3/2/2021TransMedics GroupOppenheimerBoost Price Target
10/8/2020TransMedics GroupJPMorgan Chase & Co.Downgrade
2/25/2021Semler ScientificB. RileyBoost Price Target
11/6/2020Semler ScientificLake Street CapitalBoost Price Target
10/5/2018Semler ScientificDougherty & CoInitiated Coverage
1/12/2021ViewRayPiper SandlerBoost Price Target
3/13/2020ViewRayMizuhoReiterated Rating
10/15/2019ViewRayPiper Jaffray CompaniesSet Price Target
(Data available from 4/23/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.